<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30033510</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-2307</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>473</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Virchows Archiv : an international journal of pathology</Title>                <ISOAbbreviation>Virchows Arch.</ISOAbbreviation>            </Journal>            <ArticleTitle>Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.</ArticleTitle>            <Pagination>                <MedlinePgn>275-283</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00428-018-2416-z</ELocationID>            <Abstract>                <AbstractText>We compared the characteristics, clinical behavior, and biomarker profile between HER2 positive (HER2+) and triple-negative (TN) ductal carcinoma in situ (DCIS) which are considered more aggressive than other DCIS subtypes. In addition, we explored the impact of these features on its potential of progression to invasive breast carcinomas. Cases of DCIS diagnosed at the Department of Pathology, Singapore General Hospital from 1994 to 2010 were identified. TN and HER2+ DCIS cases formed the study cohort. Immunohistochemistry (IHC) was performed for ER, PR, HER2, CK14, EGFR, and p53. Comparisons of clinicopathological features, IHC results, and clinical outcomes were performed between the two groups. We evaluated 145 HER2+ and 85 TN DCIS cases. HER2 positive DCIS had significantly higher nuclear grade (p &lt; 0.001) and more frequent necrosis (p &lt; 0.001) than TN DCIS. HER2 positive DCIS also harbored significantly higher rates of nuclear p53 immunoreactivity (p = 0.002) than TN DCIS. Younger patients (age &lt; 40) with HER2+ and TN DCIS demonstrated statistically significant worse invasive DFS than older women (p &lt; 0.001). Multivariate cox regression analysis (HR 15.08, 95% CI 12.79-81.45, p = 0.002) also confirmed these findings. In addition, younger patients (age &lt; 40) with HER2+ DCIS experienced significantly poorer prognosis when p53 was also positive (p = 0.033). HER2+ DCIS had more aggressive pathological characteristics compared to TN DCIS; accumulation of mutant p53 could possibly be contributory. Age was an independent predictor of aggressive biological behavior of HER2+ and TN DCIS. We demonstrated that younger patients with p53 positive HER2+ DCIS had significantly adverse clinical outcome.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Takahashi</LastName>                    <ForeName>Satoshi</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Anatomical Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thike</LastName>                    <ForeName>Aye Aye</ForeName>                    <Initials>AA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomical Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856, Singapore.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koh</LastName>                    <ForeName>Valerie Cui Yun</ForeName>                    <Initials>VCY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomical Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856, Singapore.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sasano</LastName>                    <ForeName>Hironobu</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tan</LastName>                    <ForeName>Puay Hoon</ForeName>                    <Initials>PH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Anatomical Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856, Singapore. tan.puay.hoon@singhealth.com.sg.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. tan.puay.hoon@singhealth.com.sg.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856, Singapore. tan.puay.hoon@singhealth.com.sg.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, MD6, #14-02T, Singapore, 117599, Singapore. tan.puay.hoon@singhealth.com.sg.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>HSRG/0009/2010</GrantID>                    <Agency>Ministry of Health -Singapore</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Virchows Arch</MedlineTA>            <NlmUniqueID>9423843</NlmUniqueID>            <ISSNLinking>0945-6317</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2006 May 15;66(10):5504-11</RefSource>                <PMID Version="1">16707480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Breast Cancer. 2011;2011:217060</RefSource>                <PMID Version="1">22295212</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2001 Apr 15;19(8):2263-71</RefSource>                <PMID Version="1">11304780</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Jul;152(2):293-304</RefSource>                <PMID Version="1">26077641</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Med Oncol. 2008;2:7-18</RefSource>                <PMID Version="1">21892261</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2007 Nov;12(11):1276-87</RefSource>                <PMID Version="1">18055847</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathol Res Pract. 2011 Jan 15;207(1):1-7</RefSource>                <PMID Version="1">21095069</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Oncol. 2013 Oct;7(5):859-69</RefSource>                <PMID Version="1">23890733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2010 Nov 30;10:653</RefSource>                <PMID Version="1">21118480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</RefSource>                <PMID Version="1">15328174</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2005 Jun 15;103(12):2481-4</RefSource>                <PMID Version="1">15884091</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Surg Pathol. 2010 Jul;34(7):956-64</RefSource>                <PMID Version="1">20495445</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2013 Jul-Aug;19(4):365-73</RefSource>                <PMID Version="1">23815268</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</RefSource>                <PMID Version="1">17438091</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 1999 Mar;187(4):396-402</RefSource>                <PMID Version="1">10398097</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Oncol. 2014 Feb;21(1):e96-e104</RefSource>                <PMID Version="1">24523627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Acad Med Singapore. 2001 Nov;30(6):671-6; quiz 677</RefSource>                <PMID Version="1">11817303</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2010 May 25;7(5):e1000279</RefSource>                <PMID Version="1">20520800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource>                <PMID Version="1">21709140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Surg Res. 2007 Jun 1;140(1):109-14</RefSource>                <PMID Version="1">17291532</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2003 Apr;10(4):431-42</RefSource>                <PMID Version="1">12719720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 1999 Dec;189(4):521-6</RefSource>                <PMID Version="1">10629552</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2007;9(1):R4</RefSource>                <PMID Version="1">17217540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Cell Biol. 2013 Jan;15(1):2-8</RefSource>                <PMID Version="1">23263379</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2017 Oct;24(10):2999-3003</RefSource>                <PMID Version="1">28766212</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2010 Jan;23(1):123-33</RefSource>                <PMID Version="1">19855377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Surg Oncol. 2011 Oct;104(5):458-65</RefSource>                <PMID Version="1">21557226</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Syst Biol. 2006;2:54</RefSource>                <PMID Version="1">17016520</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 1998 Feb;11(2):155-68</RefSource>                <PMID Version="1">9504686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Gynecol Obstet. 2009 Jul;280(1):43-8</RefSource>                <PMID Version="1">19082617</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2011 Mar;102(3):656-62</RefSource>                <PMID Version="1">21214677</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2013 Feb;34(1):1-7</RefSource>                <PMID Version="1">23208673</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2006 May;19(5):617-21</RefSource>                <PMID Version="1">16528377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):69-79</RefSource>                <PMID Version="1">26076776</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 May 20;101(10):736-50</RefSource>                <PMID Version="1">19436038</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst Monogr. 2010;2010(41):121-9</RefSource>                <PMID Version="1">20956815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Virchows Arch. 2014 Sep;465(3):275-89</RefSource>                <PMID Version="1">24973889</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 1997 Feb;42(3):283-90</RefSource>                <PMID Version="1">9065612</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2013 Oct 30;13:512</RefSource>                <PMID Version="1">24171825</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2005 Aug 15;11(16):5678-85</RefSource>                <PMID Version="1">16115903</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9</RefSource>                <PMID Version="1">19383888</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Screen. 2001;8(3):149-51</RefSource>                <PMID Version="1">11678555</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Nov 16;408(6810):307-10</RefSource>                <PMID Version="1">11099028</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathol Oncol Res. 2011 Sep;17(3):753-8</RefSource>                <PMID Version="1">21479875</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Apr;26(4):682-7</RefSource>                <PMID Version="1">25600567</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2017 May;23(3):307-314</RefSource>                <PMID Version="1">27943525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Surg Oncol. 2004 Apr;30(3):243-7</RefSource>                <PMID Version="1">15028303</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 May;26(5):1019-25</RefSource>                <PMID Version="1">25678586</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jun 7;295(21):2492-502</RefSource>                <PMID Version="1">16757721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 2013 Aug;66(8):665-70</RefSource>                <PMID Version="1">23539741</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002285" MajorTopicYN="N">Carcinoma, Intraductal, Noninfiltrating</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Biomarkers</Keyword>            <Keyword MajorTopicYN="N">Clinicopathological features</Keyword>            <Keyword MajorTopicYN="N">DCIS</Keyword>            <Keyword MajorTopicYN="N">HER2</Keyword>            <Keyword MajorTopicYN="N">Recurrence</Keyword>            <Keyword MajorTopicYN="N">Triple-negative</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30033510</ArticleId>            <ArticleId IdType="doi">10.1007/s00428-018-2416-z</ArticleId>            <ArticleId IdType="pii">10.1007/s00428-018-2416-z</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>